New Presentation

(Chicago, Illinois) October 23, 2024 — Dr. Huiping Liu, MD, PhD, co-founder of ExoMira Medicine Inc. and professor at Northwestern University Feinberg School of Medicine, chaired and presented at the Translational Breast Cancer Research session during the 26th Lynn Sage Breast Cancer Symposium, a premier national conference focused on clinical and scientific advances in breast cancer care.

Dr. Liu’s presentation, titled “Circulating Tumor Cell-Facilitated Monitoring and Antibody Targeting of Metastatic Breast Cancer,” highlighted cutting-edge strategies for leveraging circulating tumor cells (CTCs) in real-time disease monitoring and targeted therapeutic development. Her work continues to advance the scientific foundation that underpins ExoMira’s mission to develop novel cancer immunotherapies such as its lead USP22 inhibitor program, MIRA-1.

Participation in this prestigious symposium underscores ExoMira’s deep scientific roots and the translational relevance of its therapeutic platform in addressing metastatic and treatment-resistant breast cancers.